Get the Stockscreener App
0.5618
2.15%
0.0118
After Hours:
.58
0.0182
+3.24%
Century Therapeutics Inc stock is traded at $0.5618, with a volume of 782.91K.
It is up +2.15% in the last 24 hours and down -2.87% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.55
Open:
$0.5732
24h Volume:
782.91K
Relative Volume:
0.83
Market Cap:
$48.40M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.2453
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
+10.74%
1M Performance:
-2.87%
6M Performance:
-27.46%
1Y Performance:
-66.16%
1-Day Range:
$0.55
$0.5799
1-Week Range:
$0.48
$0.5799
52-Week Range:
$0.3418
$2.05
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.5618 | 47.39M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Therapeutics Q2 Earnings Miss Spells Short-Term Volatility, but Sector Resilience Remains - AInvest
Measuring Century Therapeutics Inc.’s beta against major indicesJuly 2025 Market Mood & Low Drawdown Momentum Ideas - Newser
Is it too late to sell Century Therapeutics Inc.IPO Watch & Daily Profit Maximizing Tips - Newser
Is Century Therapeutics Inc. showing insider buyingDividend Hike & AI Forecasted Stock Moves - mustnews.co.kr
How hedge fund analytics apply to Century Therapeutics Inc. stock2025 Market Overview & Fast Moving Stock Watchlists - Newser
IPSC long term stock - AInvest
Technical analysis overview for Century Therapeutics Inc. stockJuly 2025 Short Interest & Low Risk High Win Rate Picks - Newser
Century Therapeutics to Present Preclinical Data at EULAR 2025 Congress - MSN
What earnings revisions data tells us about Century Therapeutics Inc.Quarterly Profit Report & AI Based Buy and Sell Signals - Newser
Century Therapeutics (NASDAQ:IPSC) Lowered to “Sell” Rating by Wall Street Zen - Defense World
What institutions are buying Century Therapeutics Inc. stock nowWeekly Stock Analysis & Weekly Setup with High ROI Potential - Newser
Century Therapeutics 2025 Q1 Earnings Record Net Income Surges 372.8% - AInvest
Century Therapeutics Reports Q2 2025 Financials and Updates - TipRanks
Can Century Therapeutics Inc. expand its profit marginsJuly 2025 Review & Smart Swing Trading Alerts - newsyoung.net
Century Therapeutics shares fall 1.82% after-hours as patient dosing continues in CALiPSO-1 trial. - AInvest
Century Therapeutics (IPSC): Assessing the Value of Persistent Earnings Losses Amid Promising Pipeline Catalysts - AInvest
Century Therapeutics Reports Q2 Results and Leadership Change - MSN
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Century Therapeutics pushes novel cell therapy into clinical trials, extends cash runway to 2027 - Stock Titan
Earnings visualization tools for Century Therapeutics Inc.July 2025 Fed Impact & AI Optimized Trading Strategy Guides - Newser
Century Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern Forming2025 Fundamental Recap & Real-Time Market Sentiment Alerts - Newser
Century Therapeutics Inc. Recovery Likely Here’s What Data ShowsExit Ready Momentum Stock Watchlist Expanded - 선데이타임즈
Backtesting results for Century Therapeutics Inc. trading strategiesLong-Term Safety Investment Analysis Report - Newser
Philly’s biotech industry keeps losing local jobs in a volatile market - WHYY
Is Century Therapeutics Inc. showing signs of accumulationTrade Setup Builder with Custom Alerts - Newser
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
How Century Therapeutics Inc. stock performs during market volatilityStock Trading Session Highlights and Summary - Newser
Century Therapeutics (IPSC) to Release Quarterly Earnings on Thursday - Defense World
Breakout Traders Target Century Therapeutics Inc. on Recovery SetupVerified Signal From Chart Patterns Detected - beatles.ru
How does Century Therapeutics Inc. compare to its industry peersMaximize portfolio growth with expert advice - Jammu Links News
Century Therapeutics Inc. Stock Analysis and ForecastGet expert advice on portfolio optimization - Jammu Links News
Is Century Therapeutics Inc. a good long term investmentSkyrocketing returns - Jammu Links News
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Century Therapeutics Inc Stock (IPSC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carr Douglas | SVP Finance & Operations |
Jun 09 '25 |
Sale |
0.62 |
4,904 |
3,050 |
405,982 |
| Farid Adrienne | Chief Operations Officer |
Jun 09 '25 |
Sale |
0.62 |
552 |
343 |
250,141 |
| Pfeiffenberger Brent | President and CEO |
Jun 09 '25 |
Sale |
0.62 |
475 |
295 |
1,681,783 |
| Russotti Gregory | See Remarks |
Jun 09 '25 |
Sale |
0.62 |
526 |
327 |
392,047 |
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):